Breaking News

SCM Pharma Names BD Director

October 17, 2013

Bellamy brings 30 years of experience

Simon Bellamy has been appointed business development director at SCM Pharma. Mr. Bellamy will be responsible for new clinical trials business and small commercial opportunities for the company’s new $10 million facility in Newburn. He has 30 years of experience in the pharmaceutical industry. Most recently he held business development roles at Catalent Pharma Solutions and Piramal Healthcare.
 
Dianne Sharp, managing director at SCM Pharma, said, “Attracting Simon to our business is a major coup given his past experience in the contract manufacturing arena and he will no doubt add a huge amount of value to our exciting growth plans. We now have two of the finest sterile filling facilities in Europe catering for development, clinical trial projects and commercial supply, which gives Simon and his team a compelling service offering to take to the market.”
 
SCM Pharma specializes in the sterile production of products for clinical trials along with the supply of licensed drugs in niche markets. Its new facility completed a successful inspection from the MHRA this past summer.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research